Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Eduardo Dunayevich"'
Autor:
Patricio O’Donnell, Cheng Dong, Venkatesha Murthy, Mahnaz Asgharnejad, Xiaoming Du, Ann Summerfelt, Hong Lu, Lin Xu, Jens R. Wendland, Eduardo Dunayevich, Derek L. Buhl, Robert Litman, William P. Hetrick, L. Elliot Hong, Laura B. Rosen
Publikováno v:
Neuropsychopharmacology. 48:1052-1059
Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid oxidase (DAAO) inhibitor that increases the glutamate co-agonist D-serine lev
Autor:
Christoph Correll, Jean-Pierre Lindenmayer, Khody Farahmand, Eric Jen, Scott Siegert, Eduardo Dunayevich
Publikováno v:
Wednesday, April 26.
Autor:
Marta Zolnowska, Rima Nabbout, Ingrid E. Scheffer, Jonathan J. Halford, Rocío Sánchez-Carpintero, Ian Miller, Eduardo Dunayevich, Daniel Checketts, Yael Shiloh-Malawsky, Orrin Devinsky, Matthew Wong
Publikováno v:
Epilepsia. 62:2505-2517
Objective Add-on cannabidiol (CBD) reduced seizures associated with Dravet syndrome (DS) in two randomized, double-blind, placebo-controlled trials: GWPCARE1 Part B (NCT02091375) and GWPCARE2 (NCT02224703). Patients who completed GWPCARE1 Part A (NCT
Autor:
Elizabeth A. Thiele, Anup D. Patel, Orrin Devinsky, Daniel Checketts, Arie Weinstock, Wendy G. Mitchell, Antonio Gil-Nagel, Richard F.M. Chin, Michael Scott Perry, Maria Mazurkiewicz-Bełdzińska, Eduardo Dunayevich, Boudewijn Gunning, Jonathan J. Halford
Publikováno v:
Epilepsia. 62:2228-2239
Objective Lennox-Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs
Autor:
Christoph U. Correll, Jean-Pierre Lindenmayer, Khody Farahmand, Eric Jen, Scott Siegert, Eduardo Dunayevich
Publikováno v:
CNS Spectrums. 28:240-240
BackgroundValbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics, antiemetics, and other dopamin
Autor:
Daniel Checketts, Charlotte Nortvedt, Hari Bhathal, Boudewijn Gunning, Maria Mazurkiewicz-Bełdzińska, Richard F.M. Chin, Eduardo Dunayevich
Publikováno v:
Acta Neurologica Scandinavica
Gunning, B, Mazurkiewicz-beldzinska, M, Chin, R F M, Bhathal, H, Nortvedt, C, Dunayevich, E & Checketts, D 2020, ' Cannabidiol in conjunction with clobazam: analysis of four randomized-controlled trials ', Acta Neurologica Scandinavica . https://doi.org/10.1111/ane.13351
Gunning, B, Mazurkiewicz-beldzinska, M, Chin, R F M, Bhathal, H, Nortvedt, C, Dunayevich, E & Checketts, D 2020, ' Cannabidiol in conjunction with clobazam: analysis of four randomized-controlled trials ', Acta Neurologica Scandinavica . https://doi.org/10.1111/ane.13351
Objectives To assess the efficacy and safety profile of add-on cannabidiol (CBD) in patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) on clobazam and in the overall population of four randomized, controlled phase 3 trials. Methods
Autor:
Caroline M. Apovian, Xavier Pi-Sunyer, Eduardo Dunayevich, Lisette M Acevedo, Frank L. Greenway, Susan L. McElroy
Publikováno v:
International journal of obesity (2005)
Background/objectives Prolonged-release (PR) naltrexone 32 mg/bupropion 360 mg (NB) is approved for chronic weight management as an adjunct to reduced-calorie diet and increased physical activity. Central nervous system-active medications have the po
Autor:
Eduardo Dunayevich, Boudewijn Gunning, Ann Hyslop, Sameer M. Zuberi, Daniel Checketts, Deepak Madhavan, Marta Zolnowska, Jennifer Madan Cohen, Vicente Villanueva
Publikováno v:
Epilepsia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Objective We conducted a post hoc analysis of two randomized controlled trials, GWPCARE1 (NCT02091375) and GWPCARE2 (NCT02224703), to estimate the time to onset of cannabidiol (CBD) treatment effects (seizure reduction and adverse events [AEs]) in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1b10800b7ae95d590ed56b0936388c4
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14654
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14654
Autor:
Ian Miller, Russell P. Saneto, M Scott Perry, Boudewijn Gunning, Eduardo Dunayevich, Antonio Gil-Nagel, Volker Knappertz, Rocío Sánchez-Carpintero, Ingrid E. Scheffer, Daniel Checketts
Publikováno v:
JAMA Neurol
Importance Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. Objective To evaluate the efficacy and safety of a pharmaceutical for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b903591896d4b9c37817e7386e61c0b9
https://hdl.handle.net/10171/66183
https://hdl.handle.net/10171/66183
Autor:
Trina W. Walker, Anastasia Georgiades, Dana Hilt, Vicki G. Davis, George M. Haig, Eduardo Dunayevich, Michael Sand, Daniel Umbricht, Richard S.E. Keefe, Anzalee Khan, Antony Loebel, Alexandra S. Atkins
Publikováno v:
Schizophrenia Research. 190:172-179
The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establi